Peroxisome Proliferator–Activated Receptor δ Agonist GW1516 Attenuates Diet-Induced Aortic Inflammation, Insulin Resistance, and Atherosclerosis in Low-Density Lipoprotein Receptor Knockout Mice | Zendy

Lazar A. Bojic | Zendy; Amy C. Burke | Zendy; Sanjiv S. Chhoker | Zendy; Dawn E. Telford | Zendy; Brian G. Sutherland | Zendy; Jane Y. Edwards | Zendy; Cynthia G. Sawyez | Zendy; Rommel G. Tirona | Zendy; Hao Yin | Zendy; J. Geoffrey Pickering | Zendy; Murray W. Huff | Zendy

Open Access

Peroxisome Proliferator–Activated Receptor δ Agonist GW1516 Attenuates Diet-Induced Aortic Inflammation, Insulin Resistance, and Atherosclerosis in Low-Density Lipoprotein Receptor Knockout Mice

Author(s) -

Lazar A. Bojic,

Amy C. Burke,

Sanjiv S. Chhoker,

Dawn E. Telford,

Brian G. Sutherland,

Jane Y. Edwards,

Cynthia G. Sawyez,

Rommel G. Tirona,

Hao Yin,

J. Geoffrey Pickering,

Murray W. Huff

Publication year - 2013

Publication title -

arteriosclerosis thrombosis and vascular biology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.007

H-Index - 270

eISSN - 1524-4636

pISSN - 1079-5642

DOI - 10.1161/atvbaha.113.301830

Subject(s) - endocrinology , medicine , insulin resistance , proinflammatory cytokine , inflammation , peroxisome proliferator activated receptor , biology , insulin , receptor

The peroxisome proliferator-activated receptor (PPAR) δ regulates systemic lipid homeostasis and inflammation. However, the ability of PPARδ agonists to improve the pathology of pre-established lesions and whether PPARδ activation is atheroprotective in the setting of insulin resistance have not been reported. Here, we examine whether intervention with a selective PPARδ agonist corrects metabolic dysregulation and attenuates aortic inflammation and atherosclerosis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research